What medication changes are appropriate for a 31-year-old male with bipolar I disorder and attention-deficit/hyperactivity disorder (ADHD) who was previously taking lithium 300 mg twice daily and wishes to switch his treatment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Medication Change Recommendation for Bipolar I Disorder with ADHD

For a 31-year-old male with bipolar I disorder and ADHD who wishes to switch from lithium 300mg BID, the most appropriate approach is to switch to valproate (divalproex) as the primary mood stabilizer, then add a stimulant (methylphenidate or mixed amphetamine salts) once mood stability is achieved for at least several weeks. 1

Critical First Step: Understand Why He Wants to Change

Before switching, determine the reason for wanting to change medications:

  • Side effects (tremor, polyuria, weight gain, cognitive dulling)
  • Inadequate efficacy for mood symptoms
  • Uncontrolled ADHD symptoms despite mood stabilization
  • Monitoring burden (frequent blood draws)

The reason will guide the specific switch strategy.

Primary Mood Stabilizer Options

First-Line Alternatives to Lithium

Valproate (divalproex) is the strongest alternative based on guideline evidence 1:

  • FDA-approved for acute mania in adults
  • Equivalent efficacy to lithium in maintenance studies
  • May be better tolerated than lithium in some patients
  • Requires baseline and periodic monitoring: liver function tests, complete blood count, pregnancy test (every 3-6 months)

Atypical antipsychotics are also first-line options 1:

  • Aripiprazole, risperidone, quetiapine, olanzapine, or ziprasidone
  • FDA-approved for acute mania
  • Critical caveat: Significant metabolic risks (weight gain, diabetes, hyperlipidemia)
  • Requires baseline and ongoing monitoring: BMI monthly for 3 months then quarterly, fasting glucose and lipids at 3 months then yearly, blood pressure

Important Nuance on Switching

Do not abruptly discontinue lithium - withdrawal increases relapse risk dramatically, especially within 6 months 1. The evidence shows >90% relapse rate with non-compliance in adolescents 1. Taper gradually while overlapping with the new mood stabilizer.

Addressing Comorbid ADHD

Timing is Critical

ADHD treatment should only be initiated after achieving mood stability 1. The evidence is clear on this sequence:

  • Stabilize bipolar symptoms first with mood stabilizer
  • Wait for sustained euthymia (several weeks minimum)
  • Then add ADHD medication

ADHD Medication Options

First-line for ADHD in bipolar disorder 2:

  1. Bupropion - reasonable first choice, lower risk of mood destabilization
  2. Stimulants (methylphenidate or mixed amphetamine salts) - can be used if patient is at low risk for manic switch and adequately mood-stabilized

Evidence supporting stimulants: A randomized controlled trial demonstrated that mixed amphetamine salts were safe and effective for ADHD once mood was stabilized with divalproex 1. Recent large-scale data shows methylphenidate and lisdexamfetamine reduced psychiatric hospitalizations when used with mood stabilizers 3.

Second-line options 2:

  • Atomoxetine (non-stimulant)
  • Modafinil

Critical Safety Consideration

Stimulants carry risk of mood destabilization in bipolar I disorder 2, 4. However, when used with adequate mood stabilization, the evidence suggests they are relatively safe and do not increase relapse rates 1. The key is ensuring the patient is truly euthymic and on an effective mood stabilizer dose before adding stimulants.

Practical Implementation Algorithm

Step 1: Initiate New Mood Stabilizer

  • Start valproate 250-500mg BID, titrate to therapeutic level (50-125 mcg/mL)
  • OR start atypical antipsychotic at standard dosing
  • Continue lithium during overlap

Step 2: Taper Lithium Gradually

  • After 2-4 weeks on new mood stabilizer at therapeutic dose
  • Reduce lithium by 300mg every 1-2 weeks
  • Monitor closely for mood destabilization

Step 3: Achieve Sustained Mood Stability

  • Wait minimum 4-6 weeks of euthymia on new regimen
  • Confirm no manic, hypomanic, or depressive symptoms

Step 4: Add ADHD Medication

  • If choosing bupropion: Start 150mg XL daily, increase to 300mg after 1 week
  • If choosing stimulant: Start methylphenidate ER 18mg or mixed amphetamine salts XR 10mg daily, titrate slowly based on response
  • Monitor for mood destabilization, especially first 4-8 weeks

Monitoring Requirements

For valproate 1:

  • Baseline: liver function, CBC, pregnancy test
  • Ongoing: drug levels, liver function, CBC every 3-6 months
  • Watch for polycystic ovary disease in females

For atypical antipsychotics 1:

  • Baseline: BMI, waist circumference, blood pressure, fasting glucose, fasting lipids
  • BMI monthly × 3 months, then quarterly
  • Blood pressure, glucose, lipids at 3 months, then yearly
  • Monitor for extrapyramidal symptoms and tardive dyskinesia

For stimulants:

  • Blood pressure and heart rate at each visit
  • Monitor for mood symptoms, sleep disturbance, appetite suppression

Common Pitfalls to Avoid

  1. Starting ADHD medication before mood stabilization - high risk of triggering mania
  2. Abrupt lithium discontinuation - dramatically increases relapse risk
  3. Inadequate mood stabilizer dosing before adding stimulant
  4. Assuming ADHD symptoms during mood episodes are true ADHD - diagnose ADHD only during sustained euthymia 2, 4
  5. Neglecting metabolic monitoring with atypical antipsychotics

Duration of Treatment

Maintenance therapy should continue for 12-24 months minimum after mood stabilization 1. Many patients with bipolar I disorder require lifelong treatment 1. The decision to discontinue should be individualized based on relapse history, severity of episodes, and patient preference, with gradual tapering and close monitoring if attempted.

References

1
Guideline

practice parameter for the assessment and treatment of children and adolescents with bipolar disorder.

Journal of the American Academy of Child and Adolescent Psychiatry, 2007

Related Questions

What medication regimen would be appropriate for an 18‑year‑old patient with attention‑deficit/hyperactivity disorder, bipolar disorder, borderline personality disorder, and insomnia?
What is the diagnosis and recommended treatment plan for a 24-year-old female with a history of anxiety, depression, possible bipolar disorder, attention‑deficit/hyperactivity disorder (ADHD), currently taking lamotrigine (Lamictal), fluoxetine (Prozac), and hydroxyzine, who presents with depressive and anxiety symptoms, mood instability, past suicide attempt, trauma history, and medication nonadherence?
In a patient with bipolar II disorder and ADHD who is taking fluvoxamine 100 mg daily and lamotrigine 250 mg daily, can guanfacine or another medication be added to treat ADHD?
How should bupropion (Wellbutrin), lamotrigine, olanzapine, and fluoxetine be used and dosed to treat an adult with bipolar II depression and comorbid ADHD?
What is the diagnosis and recommended treatment plan for a 31-year-old female patient with a complex psychiatric history (major depressive disorder, generalized anxiety disorder, post‑traumatic stress disorder, borderline personality disorder, attention‑deficit/hyperactivity disorder, and prior schizoaffective disorder with intermittent paranoid and religious delusions and mixed manic features) who presents with chronic suicidal ideation, extreme fatigue, limited reliability as a historian, and intermittent paranoia?
What is the recommended follow‑up and is embolization of a spontaneous portosystemic shunt indicated when a contrast‑enhanced CT shows a markedly dilated superior mesenteric vein (SMV) draining into the inferior vena cava (IVC)?
How should I switch from fluoxetine (Prozac) 40 mg daily to bupropion (Wellbutrin) XL 150 mg daily?
In an 80-year-old woman with a history of depressive‑anxious disorder, prior suicide attempts, chronic tremor, hypertension, hypothyroidism, and polypharmacy (lithium, venlafaxine, mirtazapine, lorazepam as needed, propranolol, olmesartan, levothyroxine), who presented with generalized tremor, dysuria, suprapubic pain, mild renal impairment (creatinine 1.5 mg/dL) and mild cholestasis, and subsequently developed temporal‑spatial disorientation, confusion, psychomotor agitation, incoherent speech, and involuntary limb movements, what is the most likely diagnosis?
What is the recommended management for post‑COVID pulmonary fibrosis, including pharmacologic therapy, monitoring, and supportive care?
What are the clinical features, causes, and management of drug‑induced parkinsonism (DIP)?
For a hemodialysis patient taking calcium carbonate 1000 mg three times daily with meals who develops diarrhea, what alternative dosing of Tums (calcium carbonate) is recommended?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.